Regeneron Pharmaceuticals And Sanofi Announce FDA Approval For Dupixent In The U.S. As First And Only Treatment For Adolescents With Chronic Rhinosinusitis With Nasal Polyps
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals and Sanofi have received FDA approval for Dupixent as the first treatment for adolescents with chronic rhinosinusitis with nasal polyps. This expands its use to patients aged 12-17, following a priority review.
September 13, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals' Dupixent has been approved by the FDA for use in adolescents with chronic rhinosinusitis with nasal polyps, potentially boosting its market share and revenue.
The FDA approval for Dupixent in a new age group expands its market potential, likely increasing sales and enhancing Regeneron's revenue. This is a significant development for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Sanofi, in collaboration with Regeneron, has received FDA approval for Dupixent for adolescents with CRSwNP, which could enhance its product portfolio and revenue.
The FDA approval allows Sanofi to expand its product offerings and potentially increase its market share and revenue, positively impacting the company's financial outlook.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80